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This workshop will describe a methodology for estimat-
ing the costs and outcomes for a disease under different
disease management strategies. The methodology uses a
combination of published data, physician interviews, na-
tional databases, and standard reference sources and can
be applied in multiple countries. The methodology in-
cludes several steps including: (l) a review of the pub-
lished literature on disease epidemiology, treatment and
prevention efficacy, and disease management recommen-
dations; (2) interviews with physicians managing the dis-
ease to determine their treatment practices and to ask
them about the health care products and services used by
their patients; (3) use of standard references and national
data bases to validate the health care use data and to ob-
tain unit costs for health care services; (4) validation of
the results using patient data bases; and (5) combination
of all the data using spreadsheet and decision tree soft-
ware. The methodology will be illustrated using the ex-
ample of cytomegalovirus (CMV) infection and disease in
renal transplant patients. Three disease management
strategies are compared, prophylaxis (ganciclovir), testing
for virus (direct antigen testing and culture) and preemp-
tive therapy (ganciclovir), and treatment only (ganciclovir
with or without immune globulin). The cost and outcome
estimates were obtained for the US and the UK. The re-
sults can be applied by health care decision makers and
providers to understand the impact of different current
and anticipated disease management strategies on costs
and patient outcomes.
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Our Pharmacy department has previously described the
implementation of a clinical documentation system. This
computerized system is utilized by pharmacists in both
the inpatient and ambulatory care practices throughout
our institution, and allows for the comprehensive docu-
mentation of clinical activities. A major goal of the sys-
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tem is to accurately capture cost avoidances as well as
cost savings attributed to our staff through their day to
day interactions with the patients whom they serve. The
method utilized for calculating cost avoidances as previ-
ously been described, relies on hospital-specific DRG
data as a proxy in order to better quantify the impact of
our clinical interventions on the patients' length of stay.
During the initial 5,000 interventions, a series of weekly
meetings was initiated where clinical as well as adminis-
trative staff met to manually review interventions in or-
der to quantify cost savings as well as cost avoidances.
However, a significant rate limiting step for the process
was the amount of time necessary to accurately evaluate
the numerous interventions. Currently, more then 40,000
interventions have been entered into our electronic data-
base. The growing numbers of interventions docu-
mented have necessitated the development of a series of
drug specific defaults which allow for the automatic cal-
culation of cost savings and cost avoidances based on our
historical data. This method (1) offers a more streamlined
approach to the calculation of these important outcome
data; (2) decreases the time required by the financial as-
sessment committee to evaluate the economic impact of
clinical interventions; and (3) provides a more cost-effec-
tive method of obtaining this important data to provide
to hospital administrators, clinical decision makers, and
department staff.
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As treatment costs are increasingly determined from indi-
vidual level cost data, the number of proposed multivari-
able methods for use in this analysis has multiplied. These
methods involve estimation of multivariable cost func-
tions that yield predictions at the individual level, condi-
tional on interventions, patient characteristics, and other
factors. What are these methods, how are they used prop-
erly, and what are the circumstances when one method is
preferred over others? The purpose of this workshop will
be to develop skills in conducting multivariable analysis
of cost data from randomized trials. We will instruct par-
ticipants in the use of ordinary least squares regression
techniques and survival analysis techniques. We will dis-
cuss how non-normal cost data and censored cost data
are properly and improperly handled in these methods.
Participants will learn when it is appropriate to use log
transformation of costs in their analysis and how to esti-
mate unbiased treatment costs using smearing techniques.
Participants will also learn how to apply the Cox propor-
tional hazard model to analysis of costs. How does one
determine which model is best given the circumstances?
We will develop concepts important for evaluating the
superior model: predictive validity and adherence to as-
sumptions for unbiased estimators. We will present re-
